The Weekly Roundup: Discover the Latest in Canadian Health, Research Advancements, and More
In this week’s edition of our weekly recap, Canada invests $15 million to establish the Pan-Canadian Genome Library, creating a centralized database for sharing genomic data. This initiative, funded by the Canadian Institutes of Health Research (CIHR), prioritizes Indigenous control over genomic datasets. Moreover, in collaboration with CIHR, the federal government takes significant steps to advance dementia research through the Dementia Research and Innovation Funders Alliance, a collaborative initiative strengthening dementia research in the country. Additionally, CIHR and its partners are investing $26.6 million to promote integrated healthcare policies and practices, supporting 13 implementation science teams and a knowledge mobilization hub. These initiatives, led by Health Minister Mark Holland, aim to bridge the gap between research findings and practical health outcomes. The federal government introduces a comprehensive strategy renewal in response to the evolving drug landscape and COVID-19 challenges. This renewal of the Canadian Drugs and Substances Strategy, originally developed in 2016, focuses on addressing inequalities, investing in community-based programs for at-risk populations, and strengthening substance controls to combat organized crime in the illegal drug market. Furthermore, the government allocates $21 million to 54 harm-reduction projects across the country, aiming to reduce harm, save lives, and provide essential information on drug safety. In other news, the Public Health Agency of Canada reports a $150 million loss on an unfulfilled COVID-19 contract in the previous fiscal year, sparking calls for an emergency parliamentary committee meeting to investigate the potential misuse of taxpayer funds by the Conservatives and Bloc Québécois. Our clients have enjoyed the benefit of receiving daily news updates. Imagine the advantage of having real-time access to valuable information. Don’t miss out – personalize your daily news recap with us. Book a free consultation now with Delphic Research!
Can We Ever Agree on Outcomes-Based Agreements?
On October 12th, Delphic Research’s Jason Grier gave a presentation on the use of Outcomes-Based Agreements to the 22nd Annual Market Access Summit held at the Old Mill Inn in Toronto. The article below summarizes the key highlights from that presentation. 21 Months The average time between Health Canada approval (Notice of Compliance) of a new drug to the time it appears on a public formulary somewhere in this country is 21 months, earning Canada the distinction of being one of the slowest in the OECD to publicly reimburse new drugs. For orphan and rare disease drugs, this number increases to 22 months. For patients waiting to access a new medicine that could improve their quality of life, even extend their lives, this is concerning. It also has an impact on health system performance, as many new drugs have been shown to demonstrate real benefit in terms of health care utilization, including reduced hospitalization or lengths of stay. Fortunately, there is a growing recognition that – at least in some cases – new strategies are needed to address the challenge and ensure earlier access for more game-changing therapeutics. While several methods have arisen to overcome these barriers and save lives, one of the most widely discussed methods is Outcomes-Based Agreements. Challenge isn’t easy….and it’s taken a leap of faith by both manufacturers and payors alike about the need to work together on behalf of patients who stand to benefit. Outcomes-Based Agreements (OBAs) follow a “pay-per-performance” model in which the effective price of a drug is adjusted, usually on the basis of dynamic rebates and depending on how the drug performs against a series of agreed-upon metrics, monitored against real-world evidence. These might include hospitalization rates, whether a patient responds to a drug, or even whether a patient is able to return to work and normal life. These strategies are useful in helping to meet the challenge of securing timely access to new medicines for patients against the background of evidence uncertainty relative to value. In circumstances where there is limited data available to provide a high level of confidence around the clinical benefits of a drug (such as where the available data is limited to Phase II studies or in circumstances where even Phase III data may be seen as underpowered due to small patient populations), OBAs have proven particularly useful in helping to overcome these limitations, expediting access. Outcomes-Based Agreements do require a leap of faith on the part of manufacturers and payors alike but, as awareness and experience with them grows, so does a sense of confidence around the use of these strategies. Manufacturers believe in using OBAs when the need for a drug that serves a small patient population is extremely high so that the cost accrued is manageable. And while payors welcome the ability to save on the costs of drugs, many feel that rebates are often not enough to offset the high costs of drugs to begin with, both for themselves and patients. However, due to the comparative benefit of cost saving, both public and private payers have started to adopt OBAs. OBAs and other similar models of pay-per-performance administration can be found globally. The UK has adopted Managed Access Agreements (MAAs), which are time-limited arrangements for patients to access drugs while further data continues to be collected. Similar models exist in the US private sector, where 58 percent of payers adopted OBAs for prescription drugs. (Source: Avalere) Despite falling behind other countries, Canada has adopted various measures to incorporate OBAs into the healthcare system. Canada has announced a plan to invest up to $1 billion over two years into a national strategy that includes pay-for-performance models of drug reimbursement. Various stakeholders are already beginning to take this leap of faith, according to a 20Sense Report published October 31st, 2023. In September 2023, CADTH introduced a new process for time-limited recommendations. As long as gaps in evidence for a drug can be bridged within three years, recommendations may be issued for drugs with limited but promising evidence, making it easier for patients in need to access drugs faster. This was preceded by the pCPA’s Temporary Access Process, in which a public engagement questionnaire was launched in August 2023 to garner feedback regarding similar time-limited agreements. And even in June 2023, INESSS encouraged manufacturers to include “exploratory economic scenarios” in their drug submissions, many of which involved medicines of uncertain value and performance-based agreements. This has even stretched to individual regions of Canada, where New Brunswick’s Horizon Health Network has partnered with manufacturers to develop an “express lane” for those in need of specific lung cancer treatments. These are encouraging developments as they demonstrate a shared commitment on the part of both industry and payors — in spite of the economic risk — to work on the common goal of seeing beneficial medicines reach patients more quickly. 43 Days It took 43 days from Health Canada for Alberta to make Zolgensma, a ground-breaking innovation for spinal muscular atrophy (SMA) available for public reimbursement on a case-by-case basis. The manufacturer has successfully pursued OBAs like these around the world, working with payers to establish Outcomes-Based Agreements with eligible rebates within a five-year time period. Zolgensma is one of seven examples of Outcomes-Based Agreements demonstrated in preliminary findings by the RWE & OBA working gruop in their report on advancing the opportunity for Real-World Evidence and Outcomes-Based Agreements in Canada. The RWE and OBA Working Group, Co-chaired by Allison Wills and Arif Mitha, partners at 20SENSE, was launched in 2019 to develop an understanding for the potential of OBAs for the benefit of all stakeholders, ranging from manufacturers and payors to academics and people as a whole. Members of the 2022 group include AbbVie, AstraZeneca, Bayer, BioScript Solutions, Janssen, and Pfizer. This is important work as, ultimately, Canada needs to step up its game when it comes to expediting access to new medicines that patients are depending on, even in the face of uncertainty with
Weekly Top Stories: PMPRB to restart drug price reform consultations; and Federal and provincial government investments to improve life sciences and healthcare
In this week’s roundup of top stories, we have seen some movement within the Patented Medicine Prices Review Board (PMPRB) and investments in Canada’s coasts. Dr. Emily A. Reynen, an intensive care physician at Quinte Health Care Belleville General Hospital, has received a five-year appointment to the PMPRB following a rigorous merit-based selection process by the federal government. The agency is preparing for a roundtable discussion in December, although the timeline for implementing new guidelines remains uncertain. These reforms aim to reduce the cost of patented drugs in Canada but have encountered setbacks and legal challenges. So far, the only successfully implemented measure is the comparison of Canadian drug prices to those in other countries. The PMPRB is resuming consultations on drug price reform after a year-long delay, attributed to the resignation of several board members and the executive director. Canada’s drug pricing ranks third globally, trailing only the United States and Switzerland, making the need for reform all the more pressing. Shifting our focus to broader health initiatives across Canada, various regions are making significant investments in healthcare. The federal government is allocating substantial repayable contributions to six pioneering life sciences companies in Nova Scotia, with repayable contributions totaling $2,989,259. The primary focus will be on enhancing health outcomes through product improvements, increased production capacity, efficiency enhancements, and market expansion. Similarly, in British Columbia, the government is making significant investments in research infrastructure, with $2.5 million in funding through the B.C. Knowledge Development Fund. They are directing $125,000 to the Loucks Pain Management Pharmacogenomics (PMP) lab at the University of British Columbia. This lab’s mission is to improve patient outcomes, especially for young patients at the B.C. Children’s Hospital, by leveraging genetic discoveries and predictive genetic testing strategies to guide clinical decision-making. Meanwhile, the Canadian Institutes of Health Research (CIHR) are collaborating with partners to boost health research and integrated care policies and practices. Their substantial $26.6 million investment will support 13 implementation science teams and a knowledge mobilization and impact hub, fostering cooperation among researchers, policymakers, and healthcare providers. The research initiatives encompass a wide array of healthcare challenges, from implementing digital solutions for remote care to enhancing sexual health services in pharmacies, improving care coordination for individuals with long COVID and chronic pain, advancing mental health support in underserved communities, and facilitating smoother transitions from hospital to home for older adults. In the context of the broader healthcare landscape in Canada, Health Minister Mark Holland recently presented the annual report on public health. This report sheds light on the increasing frequency and intensity of emergencies, including climate-related events, as well as the ongoing impact of the COVID-19 pandemic. It advocates for a shift towards a public health approach to emergencies, focusing on foundational conditions that promote community health and resilience. This approach emphasizes community engagement, empowerment, and partnerships, particularly with marginalized populations, with a call to integrate equity considerations throughout the emergency management cycle. Moreover, alongside these public health considerations, the Fourth Annual Report on Medical Assistance in Dying (MAID) for 2022 was released. This report highlights a substantial increase in medically assisted deaths, with 13,241 MAID provisions in 2022, constituting 4.1% of all deaths in Canada and marking a significant 31.2% growth from the previous year. In addition, the Canadian Medical Association (CMA), in collaboration with MD Financial Management (MD) and Scotiabank, has introduced the Health Care Unburdened Grant. This $10 million initiative aims to reduce the administrative burden on physicians and improve patient care. The grant program will provide financial support of $500,000 to $1 million to up to 15 organizations offering innovative solutions to streamline administrative work and enhance physician well-being. This initiative addresses the pressing issue of physician burnout due to administrative tasks, as evidenced by the CMA’s National Physician Health Survey, where many physicians reported declining mental health and challenges in providing patient care due to administrative burdens. Applications for the Health Care Unburdened Grant are open until December 12, 2023, with the goal of alleviating administrative workloads and enabling physicians to focus more on patient care. These combined efforts represent a comprehensive approach to healthcare improvement in Canada, with the potential to create a more accessible system for its citizens. To know more about what is happening in your industry, book a free consultation now with Delphic Research!
Weekly Top Stories: Controversies Surrounding Medical Assistance in Dying for Drug-Addicted Individuals and $900,000 Boost for Frontline Worker Mental Health
This week’s headline stories have ignited controversy, particularly regarding government actions. One major development is Canada’s upcoming plan to legalize medical assistance in dying (MAID) for individuals struggling with drug addiction starting next spring. This move has captured the attention of drug users and advocates who’ve criticized it as “eugenics.” In British Columbia, the Canadian Society of Addiction Medicine (CSAM-SMCA) has played a crucial role in facilitating the debate on this proposal. Advocates argue that it’s unfair to exclude those with substance use disorders from MAID eligibility. On the other hand, critics, including harm reduction advocates, emphasize the need for more comprehensive public health measures. These measures encompass overdose prevention sites, opioid agonist medications, and improved access to regulated drug supplies. The debate sheds light on the ethical and practical complexities of extending MAID to individuals struggling with substance use disorders. Moreover, the conference will feature a vital discussion on “Medical Assistance in Dying where Mental Disorder is the Sole Underlying Condition (MAiD MD-SUMC),” a highly contentious upcoming law in Canada. Nova Scotia’s medical community has developed an assessment framework to determine eligibility for MAiD MD-SUMC. This framework underscores the importance of distinguishing between suicidality and a reasoned wish to die, as well as assessing vulnerability in such cases. It will be presented to conference attendees, shedding light on this complex and divisive issue in the medical field. The decision on the parliamentary vote concerning Bill #C314 has also fueled debate, as it was rejected during the 2nd reading. This outcome has led to a heated debate between proponents of more extensive MAID access and critics who’ve raised ethical concerns. It underscores the ongoing struggle to strike a harmonious balance between compassion and ethical considerations within MAID laws. Presently, eligibility for MAID is based on the presence of a “grievous and irremediable medical condition,” excluding mental illness. In related news, federal Chief Public Health Officer Dr. Theresa Tam has emphasized the need to address the effects of socioeconomic disparities on health outcomes, highlighting the challenges faced by those in lower-income groups. In Ontario, the government is investing nearly $10 million to provide on-site diagnostic services for long-term care residents. The goal is to reduce hospital visits and improve their quality of life as part of the “Your Health Plan for Connected and Convenient Care.” In Quebec, opposition health spokesperson André Fortin has urged the provincial government to provide basic medical coverage for foreign nurses addressing healthcare staff shortages. Quebec Health Minister Christian Dubé has shared data showing a decrease in patients waiting for surgeries, emphasizing the need for better coordination between healthcare facilities. In Alberta, David Shepherd, the NDP Alberta’s Critic for Health, has criticized the government for unaddressed healthcare issues. Nova Scotia faces similar criticism as citizens struggle to find family doctors, experience ER closures, and endure longer wait times, despite promises from Premier Tim Houston to address healthcare system issues. Experts from the Fraser Institute have called for more fundamental changes in healthcare reform for both the Nova Scotia and federal governments to overcome current limitations. In other notable news, the Canadian government has allocated $900,000 to address mental health challenges among frontline and essential workers who have endured prolonged stress during the COVID-19 pandemic. The funding, announced by the Honourable Hedy Fry on behalf of Minister Ya’ara Saks, will support a project led by the Dr. Peter Centre. This project is a national “train-the-trainer” mentorship initiative, providing training, tailored resources, and community support for frontline health and social service providers, including harm reduction and peer workers. This funding is part of a larger $50 million investment in Budget 2021 aimed at addressing PTSD and trauma related to the pandemic, prioritizing the mental well-being of those who have dedicated themselves to community health. This week has been marked by significant developments, controversies, and the pressing need for change, particularly in healthcare, ethics, and social responsibility. As Canada grapples with issues surrounding the legalization of medical assistance in dying for individuals with substance use disorders and addresses persistent healthcare challenges, the commitment to supporting the mental health of frontline workers shines as a beacon of hope. The allocation of funds to assist those who’ve dedicated themselves to our well-being reflects our unwavering dedication to compassion and our acknowledgment of the enduring challenges we face. These stories underscore the importance of open dialogue, thoughtful solutions, and our unwavering pursuit of a brighter future for all Canadians. Want to be on top of every news about your industry? Book a free consultation now with Delphic Research.
Weekly Top Stories: Canadian Healthcare Promising Appointments and Path Forward
In this week’s top stories, a new appointee brings fresh hope as Federal Health Minister Mark Holland appointed Peter Moreland-Giraldeau, the Chair of the Canmore Subdivision and Development Appeal Board, to the Patented Medicine Prices Review Board for a five-year term through a merit-based selection process. Moreland-Giraldeau, who holds an L.L.M in Common Law from the University of British Columbia, currently serves in a legal capacity at the Appeals Commission for Alberta Workers’ Compensation, providing counsel to the General Counsel, Commissioners, and Executive of the Commission. Minister Holland expressed that Mr. Moreland-Giraldeau’s qualifications in law and experience in the operations and decision-making of quasi-judicial bodies will be a valuable asset to the Board in fulfilling its mandate to support Canadians. Health Minister Holland also acknowledges the ongoing negotiations for a significant national health accord, highlighting the importance of tailored agreements with provinces to address their unique healthcare needs. Following discussions with provincial health counterparts, he introduces a comprehensive workforce plan aimed at addressing healthcare worker shortages and future challenges. This innovative plan encompasses a ‘nurse retention toolkit,’ simplified cross-province practice for doctors and nurses, streamlined certification processes for internationally trained health professionals, and enhanced integration of health data. Furthermore, Canadian health ministers have given their nod to a cross-Canada licensing system for healthcare workers, allowing practitioners to work across provincial borders. While these strategies have garnered widespread approval, Quebec exercises caution due to its jurisdiction over healthcare. Simultaneously, British Columbia is actively planning legislation to enhance the recognition of international credentials, particularly in the healthcare sector. The Canadian Federation of Nurses Unions emphasizes the need for collaboration between governments, employers, and unions to improve working conditions and fortify the nursing workforce with a pan-Canadian approach to workforce planning. On a similar note, the Registered Nurses’ Association of Ontario has embarked on a Fall Tour to address nursing challenges and underscore the significance of a robust nursing workforce. In addition, the Ontario Medical Association advocates for universal access to a family doctor and well-coordinated healthcare teams for all Ontarians. Meanwhile, Dr. Braden Manns urges caution when considering the dismantling of Alberta Health Services (AHS), emphasizing the vital role of integration in a high-performing healthcare system. In other news, the Parliamentary Budget Officer (PBO) has estimated that implementing a single-payer universal drug plan in Canada, starting on January 1, 2024, over a five-year period, would incur an additional cost of $11.2 billion in the first year and $13.4 billion in five years for federal and provincial governments. While total spending on prescription drugs is expected to increase, the PBO’s report suggests that a single-payer system could result in economy-wide savings through improved price negotiations, estimating cost savings of $1.4 billion in 2024-25, rising to $2.2 billion by 2027-28. The report also explores alternative coverage plans, including those for catastrophic and essential medicines. Building upon a 2017 estimate for a pharmacare plan, it considers current spending on public drug plans and potential revenue from co-pays, as stated by PBO Yves Giroux. The recent developments in the Canadian healthcare landscape showcase a commitment to addressing the unique needs of both healthcare professionals and patients. The appointment of Peter Moreland-Giraldeau to the PMPRB, along with the proposed initiatives for healthcare worker support and cross-Canada licensing, underscores the government’s dedication to improving the healthcare system. The ongoing discussions surrounding the implementation of a single-payer universal drug plan highlight the importance of balancing fiscal responsibility with the desire for accessible and affordable healthcare. As the nation navigates these complex healthcare challenges, collaboration and thoughtful decision-making will be key to ensuring the well-being of all Canadians. Stay in the know and unlock valuable insights – book a free consultation today with Delphic Research.
Weekly Top Stories: Council of Canadians Calls for Universal Pharmacare Program; and $1.6 Million Allocated for Enhanced SRH Services
In the past week, we’ve witnessed significant events with far-reaching implications for the life sciences sector. These developments touch on crucial aspects of healthcare and medication access in Canada, as well as concerns about the state of healthcare services in specific regions. The Council of Canadians has addressed an open letter to Prime Minister Justin Trudeau, Deputy Prime Minister, federal Minister of Finance Chrystia Freeland, and federal Minister of Health Mark Holland. They are urging the federal government to establish a comprehensive, publicly funded pharmacare program in Canada. Their emphasis lies in the fact that approximately 11% of the Canadian population, which accounts for over 3.4 million adults, is grappling with the challenge of affording their medications, often forcing them into difficult choices between necessities like food, rent, and prescription drugs. The letter underscores the imperative need for a universal, public, and comprehensive pharmacare program, in line with the principles of Canadian medicare. The Council firmly opposes an industry-driven “fill-the-gaps” approach, arguing that it would leave many Canadians without affordable medication access and inadequately address the issue of escalating drug costs. This call to action comes at a time of concerning drug shortages in Canada, particularly in generic drug production, which has declined by 34% since 2019, despite generics constituting three-quarters of all prescribed drugs in the country. To address this issue, a step towards increasing the local production of these medications is needed. Challenges in sourcing raw materials globally have contributed to these shortages, despite the presence of pharmaceutical giants like Apotex in Toronto and Pharmascience in Montreal. In a move to enhance access to sexual and reproductive health (SRH) services, the federal government has allocated more than $1.6 million in funding to The Endometriosis Network Canada and the Society of Obstetricians and Gynecologists of Canada (SOGC). This funding announcement coincided with World Contraception Day last September 26th. In other news, Carla Beck, the leader of the Saskatchewan New Democratic Party, has voiced concerns expressed by constituents during her party’s summer outreach efforts. People have reported difficulties in accessing healthcare services, including finding family doctors and encountering extended wait times for specialist appointments and surgeries. Ms. Beck has criticized the Saskatchewan Party for presenting an overly optimistic view of the province’s economic and social conditions, highlighting the contrasting realities faced by residents, such as increased reliance on food banks. The Saskatchewan legislature is scheduled to reconvene on October 25th. Stay informed and engaged with Delphic Research for daily strategic insights. Feel free to schedule a free consultation with us today!
Weekly Top Stories: Canada Invests $49 Million in Open Science Drug Discovery Network; Federal Government Addresses Substance Use Crisis; Metro Strike Highlights Universal Pharmacare Program Issue
In this week’s top stories, we’ll delve into how the Canadian government is addressing the substance use crisis, promoting well-being, and tackling key issues. We’ll also explore the adoption of ICH guidelines and the Metro strike, shedding light on worker concerns and emphasizing the urgent need for action. First up, the federal government is allocating a hefty $49 million from the Strategic Innovation Fund to establish the ‘Conscience Open Science Drug Discovery Network.’ This is a partnership involving 27 key players from non-profits, academia, and industry. They’re using an open-science model and AI to speed up drug discovery, tackle pandemic preparedness, rare diseases, and boost Canada’s competitiveness. This initiative is expected to attract an additional $150 million in private investment, creating over 100 projects and plenty of new job opportunities. Meanwhile, Federal Minister of Health Mark Holland and Associate Minister of Health, who also serves as the federal Minister of Mental Health and Addictions, Ya’ara Saks, have been actively involved in addressing critical healthcare issues in Canada. Their recent collaboration marked the commencement of Mental Illness Awareness Week, where they highlighted the theme of ‘Awareness, Access, and Parity for Mental Health and Substance Use Care in Canada.’ During this important event, they emphasized the importance of a compassionate approach to mental healthcare, the integration of mental health into the broader healthcare system, and the pivotal role of readily available mental health resources. In parallel, Health Canada, led by Minister Ya’ara Saks, has launched a national call for proposals for the Substance Use and Addictions Program (SUAP). This program is aimed at combatting the toxic drug and overdose crisis in the country. It comes with an impressive pledge of $144 million in funding, along with an additional $4 million earmarked for projects in Ottawa. What sets it apart is its commitment to a comprehensive approach, actively encouraging submissions from groups that have been disproportionately affected by this crisis. However, it’s worth noting that while these efforts are commendable, some addiction doctors have voiced concerns about the potential impact of the safe supply program on the ongoing opioid crisis. The government is taking these concerns seriously and is committed to addressing this pressing issue to ensure the safety and well-being of affected communities. In other news, to support these initiatives, Health Canada is adopting the International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) guidelines. This demonstrates the government’s commitment to aligning internationally, even in the face of differences with existing guidance documents. Furthermore, the government, alongside Amazon Canada and eBay Canada, has also introduced the Canadian Product Safety Pledge to address the increasing availability of unsafe products in online shopping. In light of the Metro strike’s impact on workers, all of this news carries significant importance. Nikolas Barry-Shaw, the Trade and Privatization Campaigner for the Council of Canadians, has emphasized how this strike has highlighted the need for universal pharmacare in Canada. During the strike, Metro cut off drug benefits for employees, showcasing the vulnerability of workers without workplace drug insurance. Barry-Shaw argues that a public pharmacare system would ensure drug coverage as a right for all, preventing actions like this and offering other benefits like lower costs and increased job flexibility. As we wrap up this week’s top stories, it’s clear that Canada is committed to addressing critical issues with determination and compassion. From investing in cutting-edge drug discovery to prioritizing mental health and substance use care, our nation is taking significant steps forward. Stay on top of the trends with Delphic Research! Get daily strategic insights and make an appointment for your free consultation with us right now.
Weekly Top Stories: CMA’s Concerns on Healthcare Access, Pressing Workforce Crisis, New Consultant to Ontario’s Ministry of Mental Health and Addictions
As we navigate another week filled with pivotal developments in healthcare, we’re excited to explore the latest stories influencing the landscape. Join us as we delve into concerns raised by the Canadian Medical Association about healthcare access, tackle the pressing workforce crisis, and introduce you to a seasoned consultant joining Ontario’s Ministry of Mental Health and Addiction. These stories shed light on the challenges and opportunities in our healthcare system, offering valuable insights into its evolution. The Canadian Medical Association (CMA) paints a stark and troubling picture of healthcare. In an alarmingly illuminating survey conducted in partnership with CMA in August 2023, they unveil a chilling reality— the diminishing confidence of Canadians in the healthcare system. Shockingly, only 25% expressed optimism, while a staggering 80% believed that both federal and provincial/territorial governments must prioritize healthcare more. CMA drew attention to the alarming fact that six million Canadians lack a regular primary care provider. In response, they advocate for collaborative solutions with the government, including enhancing physician mobility and promoting team-based care as essential steps to address this healthcare crisis. As we strive for improvements in our healthcare system, we cannot ignore the pressing issues within our workforce. The Canadian federal government, acutely aware of the relentless toll inflicted by the COVID-19 pandemic and the ceaseless pressures on our healthcare system, which have caused significant burnout, absences, and turnover among healthcare workers. In response to these formidable challenges they have initiated collaborations with provincial and territorial governments, as well as key stakeholders, committing a budget of nearly $200 billion in health investments, including funding for wage increases and modernization. Their plan encompasses recruitment, retention, and system modernization, emphasizing improved access to healthcare services. To drive significant change in the health workforce sector, the government established a Coalition for Action for Health Workers. This coalition, comprised of experts and representatives from various healthcare sectors, is advising the government on addressing health workforce challenges. In a related move, Ontario is extending the Temporary Locum Program to prevent rural and northern hospital ER closures, providing relief amid staffing shortages. In addition to the concerns raised by CMA regarding healthcare access, the federal government’s plan to introduce a national pharmacare plan has also come under scrutiny. Two experts at the Fraser Institute, Bacchus Barua, Director of Health Policy Studies, and Jake Fuss, Director of Fiscal Studies, caution that a more cautious approach might be necessary. This cautiousness is partly due to concerns about the cost, as estimates for a universal single-payer pharmacare program range from $15.0 billion to $32.7 billion annually, and the federal deficit is already projected to surpass $40 billion in 2023. Barua and Fuss also pointed out that it’s unclear whether a national pharmacare program covering all Canadians, regardless of income or existing coverage, will achieve its intended goals, as many Canadians already have private coverage for outpatient drugs, while provincial plans assist low-income individuals and those with chronic conditions. They recommend targeting assistance to the 8.2 to 23 percent of Canadians struggling with medication costs or expanding coverage through private sector partnerships. They caution that the implementation of a national pharmacare plan without precise targeting might lead to elevated government spending, increased debt levels, and potential challenges in ensuring access to medications for those with genuine medical needs. In parallel to these discussions on healthcare access and the national pharmacare plan, it’s noteworthy that Gilbert Sharpe, a seasoned health law consultant, has assumed a pivotal role as a consultant to Ontario’s Minister for Mental Health and Addictions, Michael Tibollo. With over three decades of expertise in healthcare advisory, including significant contributions to international projects for esteemed organizations like the World Bank and the World Health Organization, Sharpe brings a wealth of experience to his new role. During his tenure as the Director of Legal Services for the Ontario Ministry of Health, he played a crucial role in shaping legislation governing healthcare facilities and professionals. He boasts an impressive track record, having authored books on health law, numerous published articles, and a background in academia, having held esteemed positions at the University of Toronto and McMaster University. Ensuring the welfare of every Canadian demands nothing less than a concerted and cooperative effort. It hinges on the unwavering commitment of healthcare practitioners, the resolute determination of policymakers, and the profound expertise of individuals like Gilbert Sharpe. These factors play vital roles in shaping the future of healthcare. Stay informed and stay engaged with Delphic Research. Fuel your strategic insights daily. Book a free consultation now!
Weekly Top Stories: First Bilingual MAiD Curriculum, New Funding for Distress and Crisis Centres, $3.4M for Biomed Research
In Canada’s evolving life sciences sector this week, significant developments are reshaping healthcare. Highlights include new fund allocations, reforms, and efforts to address drug restrictions, all of which collectively influence the trajectory of healthcare quality and accessibility throughout Canada. The Canadian government has introduced the first accredited bilingual Medical Assistance in Dying (MAiD) Curriculum for physicians and nurse practitioners. This curriculum aims to ensure consistent and safe care for MAiD requests, including those from individuals with mental illness, chronic conditions, and structural vulnerability, while also preparing for the end of the MAiD eligibility exclusion for mental illness, set to take effect in March 2024. Meanwhile, in the field of organ transplantation, the federal administration has taken on the role of a driving force for change. The tireless efforts to enhance access to living donor kidney transplantation (LDKT) for minority communities have borne fruit. These efforts, underpinned by culturally sensitive educational resources and sustained engagement with diverse ethnic groups, have yielded an impressive 20% surge in living donor rates during 2021. This resurgence follows a period of declining organ donation and transplantation rates during the pandemic, bringing renewed hope to numerous patients. In anticipation of World Suicide Prevention Day, Minister of Mental Health and Addictions Ya’ara Saks, announced an $8 million federal funding initiative. This initiative is designed to enhance equity in distress and crisis centers, complementing the upcoming launch of the 9-8-8: Suicide Crisis Helpline, which aims to ensure equitable access to crisis services for all Canadians. Yet amidst these laudable strides, Health Canada urges vigilance as unauthorized health products continue to spread. The agency has issued alerts regarding unauthorized sexual enhancement products, skin lightening products, and workout supplements, citing potential risks associated with these products, including the presence of prescription drugs and unapproved ingredients. Notably, sexual enhancement products like “Black Panther Super 500K,” “Magnum XXL 500K,” and “Magnum XXL 9800” have been found to contain prescription drugs like levodopa and controlled substances like prasterone. Health Canada strongly advises against their use, emphasizing the importance of obtaining prescription drugs exclusively from licensed pharmacies. Health Canada has also issued a public advisory concerning nine unauthorized health products seized from a store in British Columbia. These products are misleadingly labeled to contain prescription, controlled, or over-the-counter drugs. Alarmingly, two of these products, Mentholatum Mediquick Eczema Rash Anti-Itch Cream and Mentholatum Mediquick Ointment, marketed for eczema and rash relief, have been unmasked as carriers of prednisolone valerate acetate, a prescription corticosteroid unauthorized for use in creams or ointments in Canada. Meanwhile, the Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended reimbursement for AbbVie’s Vyalev (foslevodopa foscarbidopa) for the treatment of motor fluctuations in advanced levodopa-responsive Parkinson’s disease, under specific conditions. These conditions include limiting reimbursement to patients with severe limitations in daily activities due to unpredictable movement symptom changes. It also requires prescriptions from specialized neurologists. CADTH has also conditionally recommended reimbursement for abiraterone acetate in combination with prednisolone for high-risk non-metastatic prostate cancer patients beginning long-term androgen deprivation therapy, with specific criteria to be met. Institut de recherches cliniques de Montréal (IRCM) continues its commitment to innovation with a record $3.4 million donation from the IRCM Foundation. Of this donation, $2.7 million is allocated to its four main research centers focused on cardiometabolic health, genetic and neurological diseases, cancer, and inflammation. The foundation will also dedicate $412,000 to its student research scholarship program, $96,000 to upgrading the institute’s technological capabilities with state-of-the-art equipment, and $150,000 to maintaining IRCM’s infrastructure. These recent developments in Canada’s healthcare sector underscore significant changes and challenges, emphasizing the ongoing importance of vigilance, innovation, and equitable access to quality care. Fuel your strategic insights daily. Join us at Delphic Research to explore these narratives further or schedule a consultation to dive deeper into these updates and remain well-informed about the most recent developments shaping the landscape. Book a consultation now!
Weekly Top Stories: Healthcare Quality, Apotex’s Apo-Amoxi Shortage, pCPA’s CEO
This week has brought a whirlwind of developments across the Canadian life sciences sector. Here are some important stories shaping the landscape, ranging from healthcare quality comparisons to critical budget allocations and reforms: Dr. G. B. John Mancini, a Professor of Medicine at the University of British Columbia, highlights that Canada, with its universal healthcare system, maintains high-quality healthcare. Despite Canada’s province-specific drug coverage contrasting with the more universal drug coverage under Medicare in the U.S., both countries grapple with common challenges regarding access and costs of advanced medications, which include rising out-of-pocket expenses for patients lacking drug coverage, impacting access to essential medications. Despite Canada’s commitment to high-quality healthcare, it faces an ongoing challenge in the form of medication shortages. Drug Shortages Canada has reported a persistent scarcity of Apotex’s Apo-Amoxi 125 mg (amoxicillin for oral suspension). This shortage, which began on August 9, 2022, was originally anticipated to conclude on September 1, 2023. However, the latest update extends the estimated end date to September 15, 2023. Apo-Amoxi 125 mg plays a crucial role in treating certain infections and is classified as a Tier 3 drug in Canada due to its substantial impact on the nation’s drug supply and healthcare system. To add to this, after a trial of metformin, the Canadian Agency for Drugs and Technologies in Health (CADTH) has started a streamlined drug class review of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes mellitus. This is in response to requests from public drug programs to find out how best to use these drugs. CADTH has also temporarily suspended reimbursement assessments for Pfizer Canada’s elranatamab and GlaxoSmithKline’s Jemperli, and commenced a health technology evaluation for Novocure Canada’s Optune, with a specific emphasis on its use in treating supratentorial glioblastoma. But amidst these challenges, Canada is making strides with advancements in the sector. The federal government has recently allocated nearly $1.3 million in funding from Health Canada’s Sexual and Reproductive Health Fund. This funding is poised to support projects led by the Sexuality Education Resource Centre Manitoba and the Canadian HIV/AIDS Black, African, and Caribbean Network. Their shared mission is to broaden access to critical sexual and reproductive health services across the Prairies. Aside from addressing sexual and reproductive health, the government has launched public consultations for the second legislative review of the Tobacco and Vaping Products Act (TVPA). This review seeks to tackle issues associated with tobacco use while emphasizing public health and regulatory measures. Canada is also taking proactive steps to bolster its preparedness for emergencies. The National Emergency Strategic Stockpile (NESS) is undergoing a transformation aimed at enhancing the nation’s readiness for future crises. A new plan is on the horizon, set to be unveiled next spring. This reform places priority on critical aspects such as personal protective equipment, electronic inventory management, and fostering stronger collaboration with provincial partners. These measures are designed to create a more resilient supply chain and minimize waste, drawing insights from the challenges highlighted during the COVID-19 pandemic. More great news as pan-Canadian Pharmaceutical Alliance (pCPA) welcomes Douglas Clark, former Patented Medicine Prices Review Board executive director, as its first CEO starting from September 11, 2023. His role includes leading the pCPA in accordance with its existing Strategic Plan 2022–2024 and prioritizing improvements in negotiation processes and collaboration with public and private sector partners. Canada’s life sciences sector remains dynamic and continuously evolving, characterized by its dedication to quality, accessibility, and innovation. This week’s developments highlight the progress made and the ongoing challenges that continue to shape this critical sector. Feed your strategy. Every Morning. Visit us at Delphic Research or book a consultation to delve deeper into these stories and stay informed about the latest developments.